RecruitingHypertrophic Cardiomyopathy
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Eligible age
18–75 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Sponsor: Tenaya Therapeutics
You may qualify if…
- ✓ MYBPC3 mutation
- ✓ Hypertrophic Cardiomyopathy (obstructive and nonobstructive)
- ✓ Left Ventricular Ejection Fraction ≥45%
- ✓ NYHA Functional Class II or III symptoms
- ✓ NT-proBNP ≥160pg/ml
You may not qualify if…
- ✕ High AAV9 neutralizing antibody titer
Where it's recruiting
California
La Jolla · San Francisco
Georgia
Atlanta
Massachusetts
Boston
Minnesota
Rochester
Ohio
Cincinnati · Cleveland
Oregon
Portland
Pennsylvania
Philadelphia
Texas
Houston
Source: ClinicalTrials.gov · NCT05836259 · last updated 2026-03-19